|Day Low/High||40.95 / 41.28|
|52 Wk Low/High||31.43 / 48.25|
The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.
Strong balance sheet and royalties are big positives for Innoviva.
With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.
GSK is still below the declining 200-day moving average line but a rally of $2 will challenge the line.
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
Pfizer is reportedly planning to sell its consumer healthcare business in an auction next month
European stock markets are priced almost to perfection ahead of an earnings deluge.
You would think that Nascar champion Danica Patrick would be a gear head who can talk makes, models and car parts and and car collector with garages brimming with rare autos. You would be wrong.
Ford Motor Co. leads a list of notable earnings reports being released throughout the day on Wednesday
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
You don't want to own these four 'toxic stocks'.
Technical indicators suggest GSK can see further significant gains in 2017.
Britain is the second largest market for Google, generating $7.8 billion primarily from advertising in 2016.
After another technical look at GSK, this FTSE component is still going strong.
There are nearly too many surging sectors to count.
Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.
With stocks at record highs, there are still buying opportunities, but investors should be selective.
Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.
Firms' 13F filings show how they've followed in the footsteps of the father of value investing.
As we all know, the stock market and the economy abhor uncertainty.
Stocks in the health care sector seem to have no underpinnings whatsoever.
For the week of October 24, investors await quarterly results from a slew of major companies, including Apple, along with the first estimate of third quarter GDP.
Which stocks will be most favored by the corporate-bond purchases?
This market is like a leaky helium balloon; watch out for sudden downdrafts.